| NCT06945458 | Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-04-17 | 2025-12 | 2025-12 |
| NCT06673667 | First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants | COMPLETED | PHASE1 | 2024-10-22 | 2025-04-23 | 2025-04-23 |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | COMPLETED | PHASE1 | 2023-05-15 | 2024-12-18 | 2024-12-18 |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | COMPLETED | PHASE1 | 2022-06-13 | 2023-07-28 | 2023-07-28 |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | COMPLETED | PHASE1 | 2022-05-19 | 2025-03-03 | 2025-03-03 |
| NCT04772885 | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) | COMPLETED | PHASE1 | 2021-02-23 | 2022-10-20 | 2022-10-20 |